<p>– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Ho
<p>Pivot</p> <p> (invalidation): 17.6400 Our preference</p> <p>Long positions above 17.6400 with targets at 17.8800 & 18.0300 in extension.</p> <
Leave a Comment